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y 9, 2013.he study objective was to determine whether the coronary artery disease (CAD)-associated genotype at
chromosome 9p21 modulates basal or induced expression of type I interferons (IFN-I).Background The mechanism responsible for the association between common variants in chromosome 9p21.3 and CAD
remains unclear. It has been reported that the CAD risk locus is rich in enhancer-like elements and that
chromosome looping can lead to its physical proximity with the IFN-I gene cluster, raising the possibility that the
locus inﬂuences CAD risk by modulating expression of IFN-Is.Methods We examined whether genotype at the lead CAD-associated single nucleotide polymorphism (rs1333049) in 9p21
was associated with: 1) basal levels of IFN-I in plasma from 148 healthy male subjects; 2) induction of IFN-I by Toll-
like receptor stimulants in peripheral blood mononuclear cells of 60 healthy volunteers assessed by enzyme-linked
immunosorbent assay, quantitative polymerase chain reaction, Western blot, and IFN-I bioassay; and 3) enhancer
activity of predicted IFN regulatory factor 3/7 binding sites within the 9p21 CAD risk region in reporter assays.Results No signiﬁcant effects of 9p21 genotype were observed for plasma levels of IFN-a, IFN-a21, or CXCL10, or leukocyte
induction of IFN-a, IFN-a21, IFN-b, CXCL10, or total IFN-I measured at the mRNA, protein, and biological activity
levels. There was also no enhancement of reporter activity by predicted IFN regulatory factor 3/7 binding sites in the
CAD risk locus of either genotype.Conclusions The mechanism underlying the association between common 9p21 variants and CAD does not involve differential
regulation of IFN-I responses. (J Am Coll Cardiol 2013;62:1376–81) ª 2013 by the American College of
Cardiology FoundationCommon variants in the 9p21.3 gene desert are strongly
associated with the risk of coronary artery disease (CAD) (1),
although the mechanisms responsible for this association
remain poorly understood. Harismendy et al. (2) recently re-
ported that chromosome looping permits physical proximity
of the CAD risk locus to a region downstream of the IFNA21
gene, raising the possibility that enhancers in this locus may
regulate expression of the type I interferon (IFN-I) gene cluster.
The IFN-Is, which comprise 13 interferon (IFN)-a iso-
types, IFN-b, IFN-k, IFN-ε, and IFN-u, are expressedcular Sciences, University of Leicester, British
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13; revised manuscript received July 6, 2013,from a single gene cluster on chromosome 9 located ap-
proximately 800 kb from the CAD risk interval. IFN-I is
co-induced in response to bacterial or viral nucleic acid
motifs via pattern recognition receptors, such as endosomal
Toll-like receptors (TLRs), and signal through the shared
IFN-I receptor to promote expression of genes involved in
antiviral defense.
See page 1382
The potential role played by IFN-I in atherosclerotic
disease is currently debated, because both pro- and anti-
atherogenic properties of IFN-I have been reported (3–5).
Moreover, the autoimmune disease systemic lupus eryth-
ematosus (SLE), which is thought to be driven largely by
overproduction of IFN-a, is associated with an elevated risk
of CAD (6). We therefore tested the hypothesis that 9p21
genotype regulates plasma levels of IFN-I or the capacity of
leukocytes to produce IFN-I in response to TLR stimulants.
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Abbreviations
and Acronyms
CAD = coronary artery
disease
ELISA = enzyme-linked
immunosorbent assay
IFN = interferon
IFN-I = type I interferon
IRF = interferon regulatory
factor
LD = linkage disequilibrium
ODN = oligodeoxynucleotide
PBMC = peripheral blood
mononuclear cell
SLE = systemic lupus
erythematosus
SNP = single nucleotide
polymorphism
TLR = Toll-like receptor
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1377Methods
Subjects and samples. To as-
sess the effect of 9p21 genotype
on plasma levels of IFN-I, we
analyzed stored samples from 148
healthy male subjects previously
recruited into the GRAPHIC
(Genetic Regulation of Arterial
Blood Pressure in Humans in
the Community) study (cohort 1)
(7). Sixty GRAPHIC partici-
pants homozygous for rs1333049
variants were invited to donate a
fresh blood sample for leukocyte
IFN-I production studies (cohort
2), and 32 healthy volunteers
were recruited by local advertise-
ment with approval from the
University of Leicester College of
Medicine Research Ethics Com-
mittee to study IFN-I transcriptional responses (cohort 3).
All subjects provided written, informed consent, and proce-
dures were carried out in accordance with institutional
guidelines and the Declaration of Helsinki. 9p21 CAD-risk
genotype was determined in all subjects by genotyping
the lead CAD-associated single nucleotide polymorphism
(SNP) rs1333049.
Enzyme-linked immunosorbent assays, quantitative
polymerase chain reactions, and bioassays for IFN-I.
Cytokine and C-reactive protein levels were measured by
enzyme-linked immunosorbent assay (ELISA) (R&D,
Minneapolis, Minnesota; Pierce, Waltham, Massachusetts;
and Caltag-Medsystems, Buckingham, United Kingdom).
For stimulation experiments, peripheral blood mononuclear
cells (PBMCs) (106 cells/ml) isolated from fresh venous
blood were cultured with medium alone, 50 mg/ml PolyI:C,
1 mg/ml R848, or 1.5 mmol/l CpG oligodeoxynucleotide
(ODN)-2216 (InvivoGen, San Diego, California), with or
without 2-hour pre-treatment with 100 ng/ml IFN-g
(PeproTech, Rocky Hill, New Jersey). IFN-I bioactivity
was measured at 24 h using human embryonic kidney 293
cells stably transfected with STAT2, interferon regulatory
factor (IRF)-9, and an IFN stimulated response element-9
driven reporter that is sensitive to IFN-I signaling (Inviv-
oGen Inc., San Diego, California) and compared with
a recombinant IFN-a standard curve. Immunoblots were
probed with anti–IFN-a21 (Sigma, St. Louis, Missouri)
or antiglyceraldehyde-3-phosphate dehydrogenase (Santa
Cruz Biotechnology, Inc., Santa Cruz, California). PBMC
cDNA was quantiﬁed using a Rotor-Gene Q real-time-
polymerase chain reaction cycler (Qiagen, Venlo, the
Netherlands).
Reporter assays. Four regions of the 9p21 CAD risk locus
were cloned from carriers homozygous for the risk or non-
risk rs1333049 variants into pGL3-promoter (Promega,
Figure 1 Effect of 9p21 Genotype on Plasma IFN-a, IFN-a21, CXCL10, and C-Reactive Protein
Total IFN-a (A), IFN-a21 (B), CXCL10 (C), and C-reactive protein (D) were measured in plasma of 148 healthy male volunteers (cohort 1) with CC (homozygous risk), CG, and GG
rs1333049 genotypes by enzyme-linked immunosorbent assay (ELISA); N ¼ 32, 33, and 23, respectively, for interferon (IFN)-a21.
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1378Fitchburg, Wisconsin) and sequenced for veriﬁcation of
variants in high linkage disequilibrium (LD) (R2 > 0.8)
with CAD-associated SNPs (2). Human embryonic
kidney 293 cells were transfected with TLR4/MD2,
CD14, and each reporter, and challenged with medium
alone (control), 10 mg/ml PolyI:C, or 10 ng/ml lipopoly-
saccharide for 24 h.
Statistics. The effect of genotype on plasma cytokine levels
was assessed by linear regression of log-transformed re-
sponses. Stepwise regression was used to assess the effect of
age, low-density lipoprotein cholesterol, high-density lipo-
protein cholesterol, triglycerides, systolic and diastolic blood
pressures, body mass index, and smoking status on cytokine
levels, and those found to be signiﬁcant (p < 0.05) were
adjusted for when examining the effect of genotype. PBMC
expression of cytokine mRNA and protein was analyzed by
2-way analysis of variance with Tukey’s post hoc test.
Signiﬁcance was assumed at p < 0.05.Results
Subject characteristics. The clinical characteristics of the
148 healthy male volunteers (cohort 1) whose plasma samples
were analyzed for basal levels of cytokines, 60 subjects
recruited for IFN-I secretion studies (cohort 2), and
32 healthy volunteers recruited for IFN-I transcription
studies (cohort 3) are summarized in Table 1. There were
no signiﬁcant differences by genotype of the lead CAD-
associated 9p21 SNP rs1333049 in any of the demographic,
clinical, or biochemical characteristics of these subjects.
Effect of genotype on plasma levels of IFN-Is. Because of
the extensive (>80%) similarity among the 13 IFN-a
subtypes, total plasma IFN-a was quantiﬁed using pan-
subtype reactive ELISAs. These assays revealed no effect
of 9p21 genotype on plasma total IFN-a in healthy men
(Fig. 1A). There was also no effect of genotype on plasma
IFN-a21 or the chemokine CXCL10, which is a sensitive
Figure 2 Effect of 9p21 Genotype on Induction of IFN-a
Peripheral blood mononuclear cells (PBMCs) from 60 healthy volunteers homozy-
gous for the risk (CC) or nonrisk (GG) rs1333049 variants (cohort 2) were chal-
lenged with medium alone (control), PolyI:C, R848, CpG oligodeoxynucleotide
(ODN), or CpG ODN with IFN-g priming (I-CpG). Total IFN-a was measured by ELISA
(A), and IFN-I bioactivity was measured by bioassay (B) at 24 h. IFN-a21 was
quantiﬁed in PBMC lysates by densitometry of immunoblots relative to glyceral-
dehyde-3-phosphate dehydrogenase (mean  SD) (C). GAPDH ¼ glyceraldehyde-
3-phosphate dehydrogenase; IFN ¼ interferon.
JACC Vol. 62, No. 15, 2013 Erridge et al.
October 8, 2013:1376–81 9p21 Variants Do Not Regulate Type I Interferon
1379and stable marker of IFN-I induction, or C-reactive protein
(Figs. 1B to 1D). Because ELISAs for IFN-a are known to
overestimate the fraction of IFN-I that remains biologically
active in plasma (8), we also measured IFN-I biological
activity in plasma samples by bioassay. In conﬁrmation of
earlier studies, biologically active IFN-I was below the limit
of detection (<5 pg/ml) in plasma samples from healthy
subjects in any genotype group (6).
Effect of genotype on induction of IFN-a and IFN-b.
We next examined the effect of 9p21 genotype on induction
of IFN-a by PBMCs of 60 healthy volunteers in response
to stimulants ofTLR3 (PolyI:C), TLR7/8 (R848), andTLR9
(CpG ODN). Induction of total IFN-a or CXCL10 as
measured by ELISA or total IFN-I measured by bioassay was
not modiﬁed by genotype (Figs. 2A and 2B). Because 2 SNPsin high LD with rs1333049 disrupt an IFN-g–responsive
STAT1 binding site (2), we also examined the effects of
2-hour pre-incubation with IFN-g on production of IFN-a.
These experiments revealed no capacity of IFN-g to prime for
production of IFN-a or IFN-I biological activity (Fig. 2A).
9p21 genotype also did not speciﬁcally affect induction of
IFN-a21 by CpG-ODN in cell lysates (Fig. 2C). There was
also no effect of genotype on the production of IFN-b, the
downstream chemokine CXCL10, or the inﬂammatory
cytokines interleukin-1b and interleukin-6 (Figs. 3A to 3D).
Examination of the transcriptional response to TLR4- or
TLR9-stimulation also revealed no effect of genotype on
basal levels of IFN-I mRNA or on induction of IFN-b, total
IFN-a, IFN-u, or the downstream markers of transient
IFN-I production CXCL10 and ISG-54 (Figs. 3E to 3H)
(and data not shown).
Enhancer activity of IRF3/7-rich regions in 9p21. Se-
quence analysis revealed 4 regions rich in consensus sites for
the principle IFN-I–inducing transcription factors IRF3 and
IRF7 (GAAANNGAAA), which are close to or contain
SNPs in high LD (R2 > 0.8) with CAD-associated 9p21
SNPs (Fig. 4A). However, the selected regions of either
genotype did not demonstrate appreciable enhancer activity
in unstimulated cells. Moreover, activation of IRF3 and
IRF7 (by PolyI:C) or of IRF3, IRF5, and nuclear factor
kappa B (by lipopolysaccharide) also failed to stimulate
reporter activation (Fig. 4B).
Discussion
Harismendy et al. (2) recently reported that chromosome
looping induced by IFN-g permits close physical proximity
between the 9p21 CAD risk interval and certain proximal
genes, such as CDKN2A and CDKN2B, and also the
distant IFN-I gene cluster, raising the possibility that
enhancers in the CAD risk locus may modify expression of
these genes in a genotype-dependent manner. However, we
found no effect of genotype on plasma levels of IFN-I, the
capacity of PBMC to produce IFN-a, IFN-b, or their
downstream markers via the 2 major pathways of their
induction (i.e., TLR3/4/IRF3 or TLR9/IRF7) by
ELISA, bioassay, immunoblot, and quantitative polymerase
chain reaction. As viral infections or medication could have
impacted on our ﬁndings, we took care to only include
subjects that were free of any current medication, disease, or
infection. Moreover, although putative binding sites for
IRF3 and IRF7 are present in the CAD risk region, these do
not seem to possess enhancer activity basally or on TLR
stimulation. It was also shown recently that IFN-g–depen-
dent induction of CDKN2A and CDKN2B occurs inde-
pendently of 9p21 genotype (9). Our ﬁndings are supported
by recent genetic evidence from studies of SLE, a disease that
is driven by genetic propensity to increased IFN-a produc-
tion (6,10). SLE symptoms can be triggered in humans by
the administration of IFN-a, and approximately 60% of
SLE-associated SNPs are linked to IFN-I-related genes
Figure 3 Effect of 9p21 Genotype on Induction of IFN-I mRNA and Protein
PBMCs from 32 carriers of the CC, CG, and GG variants of rs1333049 (cohort 3) were challenged with medium alone (control), 100 ng/ml lipopolysaccharide, or 1.5 mmol/l CpG
ODN. Cytokines were measured by ELISA at 24 h (A to D). Expression of IFN-b, total IFN-a, CXCL10, and ISG54 mRNA was measured at 2 h and normalized to expression of
36B4 (E to H, log2y-axis). Ctrl ¼ control; IFN ¼ interferon; IL ¼ interleukin; LPS ¼ lipopolysaccharide; ns ¼ not signiﬁcant.
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1380(6,10). Nevertheless, despite numerous robust genome-wide
association studies and meta-analyses for SLE in multiple
populations, 9p21 has not emerged as a genetic risk factor for
this disease (10).Figure 4 Enhancer Activity of Putative IRF3/7 Binding Site Clusters
Four regions (R1–R4) of the 9p21 coronary artery disease (CAD) risk locus were cloned fro
enhancer-dependent reporter construct (A). CAD-associated single nucleotide polymorphi
respectively. Human embryonic kidney 293 cells were transfected with each reporter and
enhancer. pEL is the positive control nuclear factor kappa B–sensitive reporter. Results n
0.01 versus medium alone. CAD ¼ coronary artery disease; Ctrl ¼ control; IRF ¼ interferStudy limitations. It is possible that the observed lack of
effect of genotype on IFN-I responses is due to limited study
power. On the basis of the mean and SD of log-transformed
plasma IFN-a levels in the nonrisk group, our study had anin 9p21
m subjects homozygous for the risk (CC) or nonrisk (GG) rs1333049 variants into an
sm (SNPs) and predicted IRF3/IRF7 binding sites are marked in red and green,
challenged as described in the Methods section. pGL3P is the control vector without
ormalized to co-transfected renilla reporter are presented as mean  SD (B). **p <
on regulatory factor; LPS ¼ lipopolysaccharide; NF-kB ¼ nuclear factor kappa B.
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138180% power at an alpha of 5% to detect an 18.2% difference
in log-plasma IFN-a in the risk genotype group (11.0% for
plasma CXCL10) and 80% power to detect a difference of
8.2% or 4.5% between log-IFN-a or log-IFN-I bioactivity
levels, respectively, in supernatants of CpG-ODN stimu-
lated cultures of CC and GG genotypes. Because all the
subjects studied were of European Caucasian origin, we also
cannot exclude the possibility that 9p21 genotype modulates
IFN-I production in populations or ethnicities distinct from
those examined here.
Conclusions
Our ﬁndings suggest that the mechanism by which 9p21
genotype modulates cardiovascular risk does not involve
regulation of IFN-I responses.
Reprint requests and correspondence: Dr. Clett Erridge,
Department of Cardiovascular Sciences, University of Leicester,
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